Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.25 GBX | 0.00% | -2.38% | -2.38% |
Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.38% | 106M | |
+9.35% | 45.97B | |
+52.73% | 43.93B | |
+7.37% | 42.34B | |
-8.78% | 28.27B | |
+18.40% | 27.18B | |
-21.53% | 19.44B | |
+14.59% | 13.83B | |
+32.16% | 12.4B | |
+5.58% | 11.45B |
- Stock
- Equities
- Stock Scancell Holdings plc - London S.E.
- News Scancell Holdings plc
- Scancell : to Start Trial for Novel Bivalent COVID-19 Vaccine in UK, South Africa; Shares Soar 11%